Guzzo CA et al., 2002-10: Merck-sponsored double-blind placebo-controlled dose-escalation trial in 68 healthy adults: single doses of 30-120 mg and 30/60 mg three times weekly were well tolerated, with AUC and Cmax roughly dose-proportional.
Ivermectin was generally well tolerated, with no indication of associated CNS toxicity for doses up to 10 times the highest FDA-approved dose of 200 microg/kg.
Guzzo CA et al., 2002-10: Merck-sponsored double-blind placebo-controlled dose-escalation trial in 68 healthy adults: single doses of 30-120 mg and 30/60 mg three times weekly were well tolerated, with AUC and Cmax roughly dose-proportional. C6. Study type: randomized, double-blind, placebo-controlled dose escalation (3:1 ivermectin/placebo, four panels, n=68). Country: USA. Doses: 30 or 60 mg three times a week, or 90 or 120 mg single dose (i.e. up to ~2000 mcg/kg, 10x the approved 200 mcg/kg); one panel also took a single 30 mg dose with food after washout. Route: oral. Funder: Merck Research Laboratories (authors are Merck staff, Blue Bell PA). Declared conflicts: none stated in the PubMed record; all authors were Merck employees. Product: Merck's ivermectin. Comparator: placebo. Endpoint: mydriasis by pupillometry plus general toxicity. Results: no CNS toxicity signal at up to 10x the approved dose; adverse experiences similar to placebo and did not rise with dose; Cmax dose-proportional, tmax ~4 h, t1/2 ~18 h; 30 mg with food gave 2.6x higher AUC. This is the strongest published human safety evidence for doses above the label, and it is single/repeat dosing for days, not months of daily use. Also filed as IVF-04 (claims C2, C6). Study type: randomized trial.
